

SCIENTIFIC REPORTS

OPEN

Resistance to retinopathy development in obese, diabetic and hypertensive ZSF1 rats: an exciting model to identify protective genes

Vincenza Caolo¹, Quentin Roblain^{2,3}, Julie Lecomte³, Paolo Carai¹, Linsey Peters², Ilona Cuijpers^{1,2}, Emma Louise Robinson^{1,2}, Kasper Derks⁴, Jurgen Sergeys⁵, Agnès Noël³, Elizabeth A. V. Jones¹, Lieve Moons⁵ & Stephane Heymans^{1,2,6}

Diabetic retinopathy (DR) is one of the major complications of diabetes, which eventually leads to blindness. Up to date, no animal model has yet shown all the co-morbidities often observed in DR patients. Here, we investigated whether obese 42 weeks old ZSF1 rat, which spontaneously develops diabetes, hypertension and obesity, would be a suitable model to study DR. Although arteriolar tortuosity increased in retinas from obese as compared to lean (hypertensive only) ZSF1 rats, vascular density pericyte coverage, microglia number, vascular morphology and retinal thickness were not affected by diabetes. These results show that, despite high glucose levels, obese ZSF1 rats did not develop DR. Such observations prompted us to investigate whether the expression of genes, possibly able to contain DR development, was affected. Accordingly, mRNA sequencing analysis showed that genes (i.e. *Npy* and *crystallins*), known to have a protective role, were upregulated in retinas from obese ZSF1 rats. Lack of retina damage, despite obesity, hypertension and diabetes, makes the 42 weeks of age ZSF1 rats a suitable animal model to identify genes with a protective function in DR. Further characterisation of the identified genes and downstream pathways could provide more therapeutic targets for the treat DR.

Globally, prevalence of diabetes has nearly doubled from 4.7% in 1980 to 8.5% of the adult population in 2014¹. Diabetes can lead to several complications affecting the cardiovascular system, kidneys, nerves, and eyes². Diabetic retinopathy (DR) is one of the most serious complications of diabetes. Prolonged exposure to high blood glucose levels (hyperglycemia) results in severe damage of the retinal vasculature²⁻⁴. This can lead to blurred vision, dark spots, flashing lights, and eventually total loss of vision. DR is the leading cause of blindness⁵ and makes a big contribution to the total 11.6% of annual health-care costs accounted for diabetes⁶.

Currently, several animal models are being used to study the progression of DR, for example the streptozotocin (STZ)-induced and Akimba mouse models (reviewed in³). All these models, however, present serious limitations and they do not reflect all stages of DR progression in humans. In addition, these models do not develop diabetes spontaneously, but are either chemically or genetically induced. For instance, STZ is a toxic substance that is injected in mice or rats to destroy the pancreatic β -cells^{3,7}. The Akimba mouse develops DR due to the presence of the human Vascular Endothelial Growth Factor isoform 165 (hVEGF₁₆₅) transgene, which induces an overexpression of VEGF in photoreceptors⁸. Among the few established animal models that develop diabetes spontaneously, the Zucker Diabetic Fatty (ZDF) rat represents an established model for type 2 diabetes.

¹Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven, Belgium.

²Department of Cardiology, CARIM School for Cardiovascular Diseases Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. ³Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, Liège, Belgium. ⁴Department of Genetics and Cell Biology, CARIM School for Cardiovascular Diseases Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. ⁵Laboratory of Neural Circuit Development and Regeneration, Animal Physiology and Neurobiology Section, Department of Biology, KU Leuven, Leuven, Belgium. ⁶The Netherlands Heart Institute, NI-HI, Utrecht, The Netherlands. Correspondence and requests for materials should be addressed to V.C. (email: Vincenza.caolo@kuleuven.be)

Received: 27 March 2018

Accepted: 17 July 2018

Published online: 09 August 2018




Figure 1. Arterial tortuosity index of the retinal vasculature from lean and obese ZSF1 rats, between 5 and 42 weeks old. Tortuosity index of the retinal arteries was increased in obese as compared to lean ZSF1 rat retinas of 18, 26, 34 and 42 weeks of age. No difference in arteriolar tortuosity was detected in rats of 5 and 14 weeks of age. All values are mean \pm SD, ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

However, ZDF rats did not show any clear sign of DR, i.e. vascular occlusion or regression⁹. Besides the ZDF, the obese ZDF/Spontaneously Hypertensive Heart Failure (SHHF) F1 hybrid (ZSF1) rat, which are the result of a cross between a ZDF female and a SHHF male, develops metabolic complications typical of type-2 diabetes and have a more severe phenotype than the ZDF parental strain. Both obese and lean control ZSF1 rats are hypertensive¹⁰. However, the obese ZSF1 rats are also affected by diabetic nephropathy (DN), insulin resistance, obesity, hyperinsulinemia, hypercholesterolemia, congestive heart failure, and hypertriglyceridemia¹¹. The ZSF1 rat is currently used as a model to study DN, whereas no scientific study on DR performed in these animals has been reported to date. In this study, we extensively investigated whether the ZSF1 rat could represent a suitable animal model to study the pathogenesis of DR. In order to assess the retinal vascular changes caused by diabetes, such as arteriolar tortuosity, obese and lean control ZSF1 rats were subjected to Heidelberg Retina Angiography (HRA) and additional histological analysis over a period of 42 weeks. We further examined the potential combined effect of chronic diabetes, obesity and hypertension on vasculature of retinas isolated from 6 and 42 weeks old obese and lean control ZSF1 rats, by assessing vascular density, pericyte coverage and number of microglia on whole mounted retina. The thickness of the neural retinal layers was assessed by Optical Coherence Tomography (OCT) over a period of 35 weeks. However, no differences were detected between obese and lean ZSF1 rats.

Despite the increase in vascular tortuosity, obese ZSF1 rats did not develop DR. The absence of a DR phenotype would suggest the existence of a protective gene expression profile in these rats. Consistently, deep sequencing analysis of mRNA isolated from retinas of 6 and 42 weeks old obese and lean ZSF1 rats, revealed the upregulation of several genes with a potential protective function, i.e. Neuropeptide Y (*Npy*) and several crystallin genes, at 42 weeks. Whereas genes, previously described to drive vascular inflammation, such as Intercellular Adhesion Molecule 1 (*Icam1*) and Toll-like receptor 4 (*Tlr4*) were downregulated in retinas from obese rats 42 weeks of age.

A deeper understanding on the role of *Npy* and the crystallin genes in the retina following stressful conditions such as diabetes could be beneficial for developing better tools to improve the condition of patients affected by DR and other diabetes related ocular complications.

Results

Arteriolar tortuosity is increased in obese ZSF1 rats over time. In the clinic, arteriolar tortuosity is routinely used as a marker to predict pathological neovascularization and rapid DR progression¹². Therefore we assessed arteriolar tortuosity index in lean and obese ZSF1 rats over a period of 6 to 42 weeks of age. As shown in Fig. 1, the tortuosity index significantly increased in obese rats compared to their lean controls at 18, 26, 34 and 42 weeks, but did not differ when comparing lean and obese ZSF1 rats at 5 and 14 weeks of age. Increase in weight and blood glucose levels was confirmed in obese ZSF1 rats at 18, 22 and 42 weeks as reported in Supplementary Figure 2A,B.

Retinal vascular density and pericyte coverage are not affected by diabetes or age. Besides vessel tortuosity, two characteristics of DR are pericyte dropout and pathological neovascularization. Specifically, pericyte dropout leads to capillary occlusions followed by hypoxia^{13,14}. In the initial phase, blood vessels retract due to vessel instability caused by the loss of pericytes¹⁵. This leads to hypoxic areas, which in turn increases the expression of HIF-1 and subsequent VEGFA, resulting in pathological neovascularisation^{16,17}. Remarkably, deep and superficial vascular density and pericyte coverage did not differ between lean and obese animals at 6 and 42 weeks of age, but also there was no time-induced difference in obese and lean control ZSF1 rats at 42 weeks compared to those at 6 weeks (Fig. 2B,C). These results suggest that the vascular density and pericyte coverage are not affected by both, age and diabetes in ZSF1 rats.

The number of microglia is affected by age, but not by diabetes. The activation of several signaling pathways during DR results in increased inflammation⁴. Microglia constitute the resident immune cells of the central nervous system¹⁸ and they seem to play an important role during DR progression¹⁹⁻²¹. The number of Iba1-stained microglia was significantly higher in the retinas of both lean and obese ZSF1 rats at 42 weeks as




Figure 2. Vascular density and pericyte coverage of retinal vasculature from 6 and 42 weeks old lean and obese ZSF1 rats. (A) IB4 (green), NG2 (red) and a merge signal of both the deep and superficial retinal vascular plexus. Scale = 50 μ m. (B) Quantification of vascular density of the deep and superficial plexus shown in percentage of IB4 signal of the total area ($n = 6-7$ per data point). (C) Quantification of pericyte coverage of the deep and superficial plexus shown as ratio of the NG2 and IB4 positive areas ($n = 5-7$ per data point). All values are mean \pm SD.

compared to lean and obese ZSF1 rat at 6 weeks (Fig. 3A,B), which is in line with an age-dependent increase²¹. However, the number of microglia did not differ between lean and obese ZSF1 either at 6 and 42 weeks of age (Fig. 3B), indicating that diabetes did not impact the microglia cell number in obese ZSF1 rat retinas.

The morphology of the vasculature is affected by age, but not by diabetes. Next, we determined whether obese ZSF1 rats showed any changes in the morphology of their retinal vascular network, stained with IB4, as compared to their lean controls. An illustration of junctions, segments, loops and branches is reported in Supplementary Figure 2. In the deep retinal vascular plexus, the number of junctions, segments, loops and branches were significantly decreased in 42 weeks old lean and obese rats as compared to the 6 weeks old lean and obese ZSF1 rats, respectively (Fig. 4A-D; Deep). Also, in the superficial vascular plexus, the number of junctions, segments and branches were significantly decreased in the 42 weeks old obese ZSF1 rats compared 6 weeks old obese ZSF1 rats (Fig. 4A,B,D; Superficial). No significant difference was found in the number of loops in the superficial plexus between the groups (Fig. 4C; Superficial). Finally, no significant difference was found in the number of junctions, segments, branches and loops in the superficial and deep plexus of retinal vasculature between lean and obese ZSF1 rats at 6 and 42 weeks respectively. Overall, these results indicate that the vascular morphology in the retina is affected by age, but not by diabetes in both deep and superficial plexus. Functional




Figure 3. Number of microglia located in the retinas from 6 and 42 weeks old lean and obese ZSF1 rats. (A) IB4 (green) and Iba1 (cyan) and merge signal of the deep retinal vascular plexus. Scale = 50 μ m. (B) Quantification of microglia number counted in the intermediate and deep vascular plexus ($n = 5-7$ per data point). All values are mean \pm SD, **** $P < 0.0001$.

analysis, i.e. OCT scan, of the retina was also performed. As shown in Supplementary Figure 3, no differences in neural retina were found between obese and lean rats.

Upregulation of *Npy* and several crystallin genes in retinas from obese ZSF1 rats of 42 weeks of age.

To identify genes able to prevent the onset of DR in obese ZSF1 rat, we performed sequencing of mRNA of retinas from 6 and 42 weeks old lean and obese, ZSF1 rats. Principal Component Analysis (PCA) resulted in a clear separation of lean from obese ZSF1 rats (Fig. 5). Although less pronounced, a separation based on age could be also distinguished within the lean and obese groups, i.e. 6 versus 42 weeks old lean and 6 versus 42 weeks old obese ZSF1 rats (Fig. 5).

We performed statistical analysis on all genes expressed between the different groups. A gene was considered to be expressed when at least 5 reads were found aligned in at least all samples of one of the groups. In Fig. 6, we report the differential expressed genes (DEGs) found for all the comparisons. Changes in the expression of a total of 911 protein coding genes were identified ($FC > 1.5$ False Discovery Rate (FDR) < 0.05). A large majority of the DEGs identified per comparison was unique to that specific comparison, i.e. the DEGs were not significantly regulated in the other comparisons. Ingenuity Pathway Analysis (IPA) analysis showed the differently regulated pathways within the 4 comparisons: lean vs obese 6 weeks old, lean vs obese 42 weeks old, lean 6 vs lean 42 weeks old, obese 6 vs obese 42 weeks old (Supplementary table 1–4). Noteworthy, the leptin signalling pathway appeared to be differently regulated in the obese 6 and obese 42 weeks old (Supplementary table 4), confirming the metabolic phenotype affecting old obese ZSF1 rats (Supplements, table 4).

Among genes only upregulated in the retinas from 42 weeks old ZSF1, we found Versican (*Vcan*), Forkhead Box D1 (*Foxd1*), MHC Class I Polypeptide-Related Sequence B (*Micb*) and *Npy*, whereas *Cxadr11*, as Immunoglobulin Superfamily Member 11 (*IGSF11*), and Mal-like (*Mall*) were downregulated (Fig. 7). Remarkably, among the top regulated genes in retina from 6 vs 42 weeks old obese ZSF1, were several members of the crystallin gene family (Fig. 8). Among them, *Crybb3*, *Cryba2*, *Crygc*, *Crygb*, *Crygf*, *Crybb2*, *Cryba1*, *Cryba4*, *Crygs*, were upregulated in obese 42 as compared to obese 6 weeks old. However, *Crybb3*, *Cryba2*, *Crygc*, *Crygb*, *Crygf*, *Cryba1* were only upregulated in obese 42, indicating that their expression was likely affected by diabetes and metabolic diseases. On the other hand, *Icam1* and *Trl4*, both known to play a determinant role during vascular inflammation, were both downregulated in retinas from obese rat 42 weeks old (Fig. 9).

Discussion

The ZSF1 rat, despite being obese, hypertensive, diabetic and hyperlipidemic, did not present any clear vascular defects in their retinas that could be attributed to progressive DR. Although vascular tortuosity increased in the diabetic rats over time, vascular density and pericyte coverage did not differ between diabetic and non-diabetic rats of 6 and 42 weeks of age. Microglia number and vascular network morphology differed in aged rats, but were unaffected by diabetes. Thickness of neural retina layers were also assessed by OCT scan, however no differences




Figure 4. Quantification of vascular network morphology of the vascular deep and superficial plexus of retinas from 6 and 42 weeks old lean and obese ZSF1 rat. Number of junctions (A), segments (B), loops (C) and branches (D) in the deep and superficial retinal vascular plexus ($n = 5-7$ per data point). All values are mean \pm SD, * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

were found at the different analysed time points, in lean and obese rats. Absence of damage in the retinas from diabetic aged ZSF1 rats offered us the existing opportunity to investigate on possible molecular mechanisms that would prevent these animals from developing DR. We, therefore, performed mRNA sequencing in order to identify genes differentially expressed in retina isolated from lean and obese ZSF1 rats 6 and 42 weeks of age with a possible protective role against DR.

The RNA sequencing revealed that 85 genes were upregulated in the retinas from 42 weeks old when compared to their lean control ZSF1 rats. Among the regulated genes, we found genes known to play a role in angiogenesis, inflammation, cellular stress and death. We found that genes involved in the process of angiogenesis,




Figure 5. Principal component analysis (PCA) plot based on the first two (PC1–PC2) components of mRNA from retinas from 6 and 42 weeks old lean and obese ZSF rats.




Figure 6. Venn diagram showing overlap between the differentially expressed genes (DEG) found in different comparisons, i.e. by age (Lean 6 vs Lean 42, purple and Obese 6 vs Obese 42, gray) and diabetes and metabolic syndrome (Lean 6 vs Obese 6, green and Lean 42 vs Lean 42, blue). The cut-offs for the DEGs were set to a Fold Change \leq or \geq 1.5 and (FDR) $<$ 0.05. The numbers in the circle depict the number of DEGs found for that specific condition: i.e. in the bottom circle 51 DEGs are found in both Lean 6 vs Lean 42 and Lean 42 vs Obese 42.

i.e. *VCAN* and *Foxd1*, were upregulated. In addition, the expression of the *Micb* gene, whose increase has been associated with degeneration of retinal ganglionic cells (RGC) and development of glaucoma²², was upregulated in retinas from 42 weeks old ZSF1 rats. On the other hand, *Cxadr11*, important for excitatory synaptic localization and plasticity, and *Mall*, encoding a component of raft mediated trafficking in endothelial cells, were both downregulated. Although changes in expression of the above mentioned genes, together with increased vascular tortuosity, would suggest that an initial vascular and neuronal damage of the retinas in ZSF1 rats 42 weeks of age is occurring, we also found that several genes with a potential protective function, i.e. *Npy* and several crystallin genes, were significantly upregulated in retinas from 42 weeks old ZSF1 rats. Conversely, genes involved in vascular inflammation, like *Icam1* and *Tnfr4*^{23,24}, were downregulated in retinas from 42 weeks old ZSF1 rats.

Npy was first isolated in 1982 and is highly conserved between species²⁵. In the retina, *Npy* seems to be required during development being expressed in different cell types²⁶. Specifically, the neuroprotective role of *Npy* against excitotoxicity has been largely documented^{27–29}. As such, *Npy* was shown to reduce the $[Ca^{2+}]_i$ increase in rat neurons preventing their death³⁰. The activation of several *Npy* receptors has been reported to protect retinal cells from necrosis or glutamate induced cell death³¹. *Npy* and its receptors are expressed in retinal endothelial cells, likely playing a role in retinal related vascular diseases³⁰. In support of this, few studies have shown that Leucine to Proline polymorphism in the *Npy* gene was related to an increased predisposition to develop diabetic retinopathy in type 2 diabetic patients^{32–34}. However, results on the role of *Npy* in oxygen-induced retinopathy model have been controversial. Whereas two studies^{33,35} suggested a positive role for *Npy* in the progression of neovascularization during DR, Schmid and collaborators³⁶ reported a decreased expression level of *Npy* in a similar model. Therefore, further research is still needed to clarify the exact contribution of *Npy* in retinal vascular diseases.

Several crystallin genes were also found to be upregulated in retinas of obese ZSF1 when compared to lean 42 weeks of age. The crystallin genes were first described to encode structural proteins of the lens³⁷, but they are also expressed in other tissues and organs such as the retina³⁸, heart³⁹ and skeletal muscle⁴⁰. The crystallins are divided in two families: the α -crystallin belonging to the small heat shock proteins (sHSP) and the β - and γ -crystallins




Figure 7. Heat map displaying fold changes of the differential expressed genes. The colors are ranging from red ($-1 \leq \log_2$ Fold Change (FC)) to orange (FC ~ 0) to green (FC ≥ 1).




Figure 8. Heat map displaying fold changes of the differential expressed crystallin (Crys) genes. The colors are ranging from blue ($-2 \leq \log_2$ Fold Change (FC)) to green (FC ~ 0) to yellow (FC ≥ 2).

forming the β/γ superfamily. Besides their function in lens transparency and reflex index, the α -crystallins are induced in response to stress and injury, displaying molecular chaperone and anti-apoptotic activity⁴¹. The β/γ crystallins regulate vascular remodelling during eye development and RCG axon regeneration⁴². Crystallin gene




Figure 9. Heat map displaying fold changes for genes indicated. The colors are ranging from white ($-1 \leq \log_2$ Fold Change (FC)) to light blue (FC ≈ 0) to dark blue/violet (FC ≥ 1).

expression is altered upon DR³⁸, but their exact function during this process remains controversial. Although few studies have suggested a protective role of α B-crystallin genes against pathological neovascularization of the retina during diabetes, one study reported that delivery by intravitreal injection of recombinant adenovirus expressing α A-crystallin prevented vascular leakage and decreased pericyte loss in STZ-induced mouse model of diabetes^{43–46}. The majority of those studies, however, investigated the role of α -crystallin genes during DR, whereas little is still known on the role of β/γ crystallins. From our RNA sequencing analysis, it emerges that diabetes and the metabolic syndrome induce the expression of crystallin β (i.e. Crybb3, Cryba2, Cryba1) and γ (i.e. Crygc, Crygb, Crygf) in the retina, whereas we did not observe any significant effect on α crystallins.

Noteworthy, β and γ crystallin genes are upregulated in the retina of Nuc1 mutant rats as compared to wild type littermates⁴⁷. Nuc1 mutants are characterized by a spontaneous mutation that affects neuronal and vascular remodelling and retinal function⁴⁸. In particular, astrocytes at the vascular front seem to express β and γ crystallins together with VEGF. Moreover, in human persistent fetal vasculature (PFV) disease, in which the hyaloid vasculature does not regress normally, astrocytes expressed β and γ crystallins⁴⁷, suggesting a role for those crystallins in vascular stabilization in the eye. Besides being vasculoprotective, β/γ crystallins may also modulate axon regeneration⁴⁹. β/γ crystallins induce ciliary neurotrophic factor (CNTF) and brain derived neurotrophic factor (BDNF) both *in vitro* and *in vivo*⁴⁹. In particular Crybb2 is secreted by cultured retinas during axon regeneration, and induces axon elongation in cultured RGC axons⁴². In conclusion, β/γ crystallin genes, which are upregulated in the retinas of 42 weeks old obese ZSF1 rats, might play a role in vascular stabilization and neuronal survival, preventing ZSF1 rats from developing DR.

Vascular inflammation and leukostasis are early events in diabetic retinopathy with serious functional consequences. During DR leukocytes adhere to endothelial cells, causing vascular occlusion, macrophage accumulation and vascular tissue damage⁵⁰. Several are the genes involved in these processes. Among them, Tumor Necrosis Factor α (Tnf α) modulates endothelial cell permeability and adhesion molecule expression⁵¹. Also, the expression of CD11a, CD11b, and CD18 integrins was shown to be increased on the surface of neutrophils from diabetic rats⁵⁰. Proteins such as, Tnf α , NF-kB and Trl4 have been extensively shown to regulate the inflammatory response²³. Finally Icam1 inhibition was reported to prevent diabetic retinal leukostasis and blood-retinal barrier breakdown²⁴. Therefore, we assessed the expression of all these vascular inflammation markers and to our surprise we found that *Icam1* and *Trl4* were downregulated in in retinas from 42 weeks old ZSF1 rats, likely contributing to the protective mechanisms by reducing leukostasis and inflammation.

Although the diabetic, hypertensive, obese and hyperlipidemic ZSF1 rat does not develop overt DR, it represent a useful model to identify new molecular signalling pathways beneficial to prevent the onset of DR. Remarkably, RNA sequencing analysis led us to identify *Npy*, β/γ crystalline, *Icam1* and *Trl4* genes that are differentially expressed in lean and obese ZSF1 rats and could play a role in protecting old obese ZSF1 rats from developing DR. The roles that *Npy* and β/γ crystallins play in vascular remodelling and axon regeneration, and that *Icam1* and *Trl4* play in vascular inflammation, make them interesting candidates for new studies to target a complex ocular disease such as DR. Further characterization of the molecular mechanisms regulated by β/γ crystallins and *Npy*, *Icam1* and *Trl4*, whose activation might be protective against DR, could possibly help us to design novel and more effective therapeutic strategies to improve the clinical outcome of patients affected by DR.

Methods

Animals. All animal procedures conformed to the relevant guidelines and regulations of, and were approved by, the Animal Welfare Committee of the KU Leuven University. Male obese ZSF1 rats (ZSF1-Lepr^{fa}Lepr^{cp}/Crl) (Charles River Inc.) were used in this study. Male lean, non-diabetic, non-obese, but hypertensive ZSF1 rats were used as control. Rats were sacrificed at 6 and 42 weeks of age. The weight of each overnight fasting rat was recorded. Diabetes was confirmed after blood collection from rat tails at different time points (18, 22 and 42 weeks) and glucose levels were determined with an automated glucose analyzer device (Glucometer, Menarini Diagnostics).

Heidelberg Retinal Angiography. Rats were anesthetized by intraperitoneal injection of ketamine (Ketalar, 10 mg/mL) at a dose of 6.0 mg/kg and medetomidine hydrochloride (Domitor, 1.0 mg/mL) at a dose of 0.4 mg/kg. Rats were injected intraperitoneally with 1 mL fluorescein sodium salt (Sigma, F6377-100G) 10% solution in saline. After the experiment, rats were awakened by intraperitoneal injection of atipamezole hydrochloride (Antisedan, 5 mg/ml) at a dose of 0.5 mg/kg. Images were taken using a Heidelberg Retina Angiograph 2 (HRA2) (Heidelberg Engineering GmbH) according to the manufacturer's recommendations. Tortuosity index was calculated from these photographs using the ImageJ software as previously described⁵².

Retina Isolation and Immunofluorescence. Retina isolation and staining were carried out as previously described⁵³. Blood vessels were stained with 20 µg/mL Isolectin GS-IB4 (IB4) (I21411, Thermo Fisher). Pericytes were stained with 5 µg/mL primary antibody Mouse anti-NG2 (Cat. No. NG2 37-2700 Invitrogen) and microglia were stained with 2 µg/mL primary polyclonal antibody Rabbit anti-Iba1 (019_19741, Wako Laboratory Chemicals). 1:100 Goat anti-Mouse Alexa 568 (A11031, Molecular Probes) and 1:100 Donkey anti-Rabbit Alexa 647 (A31573, Invitrogen) were used as secondary antibodies. Photos were taken using a Leica DFC350 FX digital camera or Leica TCS SPE confocal.

The images were processed and analyzed in ImageJ. The superficial and deep vascular plexus were separated based on the IB4 images. All analyses were performed on 20X magnification images with ImageJ Angiogenesis Analyzer. This tool allows detailed quantification of several vasculature structures, such as number of junctions, segments, loops and branches as shown in Supplementary Figure 2. Junctions were defined as meeting points of segments and/or branches. Segments were described as elements between two junctions and branches are elements between a junction and extremity. Loops were defined as areas enclosed by segments⁵⁴. The percentage of IB4 positive areas was evaluated to determine vascular density. The percentage of NG2 positive areas was measured and the ratio of IB4 and NG2 positive areas was calculated to determine pericyte coverage. For area calculations, the images were quantified by ImageJ Area Fraction analysis. Microglia were quantified by ImageJ Cell Counter analysis.

Optical Coherence Tomography. To assess thickness of the retinal layers and retinal morphology, a spectral domain optical coherence tomography (SD-OCT) system (Envisu R2210, Bioptigen, Morrisville, NC, USA) was used. To evaluate retinal morphology and neural retinal thickness an InVivoVue Diver 2.2 software (Bioptigen) was used as previously described in⁵⁵.

RNA isolation and integrity. RNA was isolated from the ZSF1 retinas using the mirVana™ miRNA Isolation Kit (Cat. No 1560, Ambion) according to the mirVana™ miRNA Isolation kit protocol. In a 20 µL reaction volume, 1 µg RNA per sample was reverse transcribed into cDNA via the miScript II RT Kit (Cat. No. 218160, Qiagen), according to the manufacturer's instructions using the 5x miScript HiFlex Buffer.

The integrity of the RNA from each sample was scored on the Agilent 2100 Bioanalyzer (Agilent) by using an Expert Eukaryote Total RNA Pico chip according manufacturer's protocol. Samples that had an RNA Integrity Number (RIN) value of over 6 were subsequently used for mRNA sequence library generation.

mRNA sequencing library generation. The mRNA sequencing library was generated using TruSeq mRNA sample preparation kit (Illumina) according to manufacturer's protocol. In short, mRNA was enriched using magnetic beads coated with poly-dT, followed by fragmentation. The fragmented mRNA-enriched samples were subjected to cDNA synthesis by reverse transcriptase, followed by dA-tailing and ligation of specific double-stranded bar-coded adapters. Subsequently, a 15 cycles library amplification was performed and after clean-up, the sizes of the libraries were determined on an Agilent 2100 Bioanalyzer (Agilent) via an DNA 1000 chip according manufacturer's protocol. Pooled libraries consisting of equal molar samples were sequenced on a high-output 75 bp single read on the NextSeq500 (Illumina).

Total RNA analysis pipeline. The analyses of sequencing datasets were performed as earlier described⁵⁶. In short, reads were aligned to the rat rn6 reference genome using TopHat⁴³ and exonic reads were summed per transcript and transcripts were referred to as being expressed when at least five aligned reads were present in all samples of at least one of the groups.

Pathway analysis. The differentially transcribed genes for the obese, i.e. 6 and 42 weeks, or lean, i.e. 6 and 42 weeks, ZSF1 rats were investigated for over-represented pathways. We used normalized count reads, i.e. counts per million and log₂ transformed, and performed a pathway enrichment analysis with Ingenuity pathway analysis (IPA) software.

Statistics. Statistical analysis was performed by using GraphPad Prism 6. Statistical differences were examined by applying one and two-way analysis of variance tests (ANOVAs) followed by Tukey's Multiple Comparison Test. A *p* value of less than 0.05 (*P* < 0.05) was considered statistically significant. Data are presented as the mean ± standard deviation (SD) or ± standard error of the mean (SEM) of 5–7 retinas per group.

Data availability. All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

References

1. WHO. Global report on diabetes. (Geneva, 2016).
2. Federation, I. D. IDF Diabetes Atlas, 7th edn. (Brussels, Belgium, 2015).
3. Cai, X. & McGinnis, J. F. Diabetic Retinopathy: Animal Models, Therapies, and Perspectives. *Journal of Diabetes Research* **2016**, 3789217 (2016).

4. Hendrick, A. M., Gibson, M. V. & Kulshreshtha, A. Diabetic Retinopathy. *Primary Care: Clinics in Office Practice* **42**, 451–464 (2015).
5. Lee, R., Wong, T. Y. & Sabanayagam, C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye and Vision* **2**, 17 (2015).
6. Zheng, Y., He, M. & Congdon, N. The worldwide epidemic of diabetic retinopathy. *Indian Journal of Ophthalmology* **60**, 428–431 (2012).
7. Jiang, X., Yang, L. & Luo, Y. Animal Models of Diabetic Retinopathy. *Current Eye Research* **40**, 761–771 (2015).
8. Rakoczy, E. P. *et al.* Characterization of a mouse model of hyperglycemia and retinal neovascularization. *The American journal of pathology* **177**, 2659–2670 (2010).
9. Behl, Y. *et al.* Diabetes-Enhanced Tumor Necrosis Factor- α Production Promotes Apoptosis and the Loss of Retinal Microvascular Cells in Type 1 and Type 2 Models of Diabetic Retinopathy. *The American Journal of Pathology* **172**, 1411–1418 (2008).
10. Griffin, K. A. *et al.* Dynamic blood pressure load and nephropathy in the ZSF1 (fa/fa cp) model of type 2 diabetes. *American Journal of Physiology - Renal Physiology* **293**, F1605 (2007).
11. Dominguez, J. H. *et al.* Renal injury: Similarities and differences in male and female rats with the metabolic syndrome. *Kidney Int* **69**, 1969–1976 (2006).
12. Sasongko, M. B. *et al.* Retinal Vessel Tortuosity and Its Relation to Traditional and Novel Vascular Risk Markers in Persons with Diabetes. *Current eye research* **41**, 551–557 (2016).
13. Arboleda-Velasquez, J. F., Valdez, C. N., Marko, C. K. & D'Amore, P. A. From pathobiology to the targeting of pericytes for the treatment of diabetic retinopathy. *Current diabetes reports* **15**, 573 (2015).
14. Hammes, H. P. *et al.* Pericytes and the pathogenesis of diabetic retinopathy. *Diabetes* **51**, 3107–3112 (2002).
15. Korn, C. & Augustin Hellmut G. Mechanisms of Vessel Pruning and Regression. *Developmental cell* **34**, 5–17 (2015).
16. Ciulla, T. A., Amador, A. G. & Zinman, B. Diabetic Retinopathy and Diabetic Macular Edema. *Diabetes Care* **26**, 2653 (2003).
17. Semenza, G. L. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* **3**, 721–732 (2003).
18. Grigsby, J. G. *et al.* The Role of Microglia in Diabetic Retinopathy. *Journal of Ophthalmology* **2014**, 15 (2014).
19. Madeira, M. H. *et al.* Contribution of Microglia-Mediated Neuroinflammation to Retinal Degenerative Diseases. *Mediators of Inflammation* **2015**, 15 (2015).
20. Omri, S. *et al.* Microglia/Macrophages Migrate through Retinal Epithelium Barrier by a Transcellular Route in Diabetic Retinopathy: Role of PKC ζ in the Goto Kakizaki Rat Model. *The American Journal of Pathology* **179**, 942–953 (2011).
21. Damani, M. R. *et al.* Age-related Alterations in the Dynamic Behavior of Microglia. *Aging cell* **10**, 263–276 (2011).
22. Nowroozpoor-Dailami, K., Mirabi, A. M., Tehrani, M. & Ajami, A. Aqueous humor and serum concentrations of soluble MICA and MICB in glaucoma patients. *Iranian journal of immunology: IJI* **11**, 275–281 (2014).
23. Baker, R. G., Hayden, M. S. & Ghosh, S. NF- κ B, inflammation, and metabolic disease. *Cell Metab* **13**, 11–22 (2011).
24. Miyamoto, K. *et al.* Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. *Proceedings of the National Academy of Sciences of the United States of America* **96**, 10836–10841 (1999).
25. Tatemoto, K., Carlquist, M. & Mutt, V. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. *Nature* **296**, 659–660 (1982).
26. Santos-Carvalho, A., Ambrosio, A. F. & Cavadas, C. Neuropeptide Y system in the retina: From localization to function. *Progress in retinal and eye research* **47**, 19–37 (2015).
27. Alvaro, A. R. *et al.* Neuropeptide Y protects retinal neural cells against cell death induced by ecstasy. *Neuroscience* **152**, 97–105 (2008).
28. Santos-Carvalho, A., Elvas, F., Alvaro, A. R., Ambrosio, A. F. & Cavadas, C. Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. *Cell death & disease* **4**, e636 (2013).
29. Silva, A. P. *et al.* Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* **17**, 1118–1120 (2003).
30. Alvaro, A. R. *et al.* NPY in rat retina is present in neurons, in endothelial cells and also in microglial and Muller cells. *Neurochemistry international* **50**, 757–763 (2007).
31. Santos-Carvalho, A., Aveleira, C. A., Elvas, F., Ambrosio, A. F. & Cavadas, C. Neuropeptide Y receptors Y1 and Y2 are present in neurons and glial cells in rat retinal cells in culture. *Investigative ophthalmology & visual science* **54**, 429–443 (2013).
32. Jaakkola, U. *et al.* The Leu7Pro polymorphism of neuropeptide Y is associated with younger age of onset of type 2 diabetes mellitus and increased risk for nephropathy in subjects with diabetic retinopathy. *Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association* **114**, 147–152 (2006).
33. Koulou, M. *et al.* Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. *Annals of medicine* **36**, 232–240 (2004).
34. Niskanen, L. *et al.* Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. *Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association* **108**, 235–236 (2000).
35. Yoon, H. Z., Yan, Y., Geng, Y. & Higgins, R. D. Neuropeptide Y expression in a mouse model of oxygen-induced retinopathy. *Clinical & experimental ophthalmology* **30**, 424–429 (2002).
36. Schmid, E. *et al.* Secretoneurin, substance P and neuropeptide Y in the oxygen-induced retinopathy in C57Bl/6N mice. *Peptides* **37**, 252–257 (2012).
37. Wang, X., Garcia, C. M., Shui, Y. B. & Beebe, D. C. Expression and regulation of alpha-, beta-, and gamma-crystallins in mammalian lens epithelial cells. *Investigative ophthalmology & visual science* **45**, 3608–3619 (2004).
38. Fort, P. E., Freeman, W. M., Losiewicz, M. K., Singh, R. S. & Gardner, T. W. The retinal proteome in experimental diabetic retinopathy: up-regulation of crystallins and reversal by systemic and periocular insulin. *Molecular & cellular proteomics: MCP* **8**, 767–779 (2009).
39. Reddy, V. S., Kumar, C. U. & Reddy, G. B. Effect of chronic hyperglycemia on crystallin levels in rat lens. *Biochemical and biophysical research communications* **446**, 602–607 (2014).
40. Reddy, V. S., Jakhota, S., Reddy, P. Y. & Reddy, G. B. Hyperglycemia induced expression, phosphorylation, and translocation of alphaB-crystallin in rat skeletal muscle. *IUBMB life* **67**, 291–299 (2015).
41. Horwitz, J. Alpha-crystallin can function as a molecular chaperone. *Proceedings of the National Academy of Sciences of the United States of America* **89**, 10449–10453 (1992).
42. Liedtke, T., Schwamborn, J. C., Schroer, U. & Thanos, S. Elongation of axons during regeneration involves retinal crystallin betab2 (crybb2). *Molecular & cellular proteomics: MCP* **6**, 895–907 (2007).
43. Kim, D. *et al.* TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome biology* **14**, R36 (2013).
44. Chen, W., Lu, Q., Lu, L. & Guan, H. Increased levels of alphaB-crystallin in vitreous fluid of patients with proliferative diabetic retinopathy and correlation with vascular endothelial growth factor. *Clinical & experimental ophthalmology* **45**, 379–384 (2017).
45. Kim, Y. H. *et al.* Reduction of experimental diabetic vascular leakage and pericyte apoptosis in mice by delivery of alphaA-crystallin with a recombinant adenovirus. *Diabetologia* **55**, 2835–2844 (2012).
46. Kase, S. *et al.* alphaB-crystallin regulation of angiogenesis by modulation of VEGF. *Blood* **115**, 3398–3406 (2010).

47. Zhang, C. *et al.* A potential role for beta- and gamma-crystallins in the vascular remodeling of the eye. *Developmental dynamics: an official publication of the American Association of Anatomists* **234**, 36–47 (2005).
48. Sinha, D. *et al.* A spontaneous mutation affects programmed cell death during development of the rat eye. *Experimental eye research* **80**, 323–335 (2005).
49. Fischer, D., Hauk, T. G., Muller, A. & Thanos, S. Crystallins of the beta/gamma-superfamily mimic the effects of lens injury and promote axon regeneration. *Molecular and cellular neurosciences* **37**, 471–479 (2008).
50. Barouch, F. C. *et al.* Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. *Investigative ophthalmology & visual science* **41**, 1153–1158 (2000).
51. Penfold, P. L., Wen, L., Madigan, M. C., King, N. J. & Provis, J. M. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. *Investigative ophthalmology & visual science* **43**, 3125–3130 (2002).
52. Scott, A., Powner, M. B. & Fruttiger, M. Quantification of vascular tortuosity as an early outcome measure in oxygen induced retinopathy (OIR). *Experimental eye research* **120**, 55–60 (2014).
53. Sawamiphak, S., Ritter, M. & Acker-Palmer, A. Preparation of retinal explant cultures to study *ex vivo* tip endothelial cell responses. *Nature protocols* **5**, 1659–1665 (2010).
54. Carpentier, G. Contribution: Angiogenesis Analyzer. Vol. 2012 (ImageJ News, 2012).
55. Van Hove, I. *et al.* MMP-3 Deficiency Alleviates Endotoxin-Induced Acute Inflammation in the Posterior Eye Segment. *Int J Mol Sci* **17**(2016).
56. Derks, K. W. *et al.* Deciphering the RNA landscape by RNAome sequencing. *RNA biology* **12**, 30–42 (2015).

Acknowledgements

The research leading to these results has received co-funding from the European Union Commission's Seventh Framework Programme under grant agreement N° 305507 (HOMAGE), co-funded by the C3 project "Vision Core Leuven" of the Leuven University (IOF grant – C32/16/004). Hercules Foundation (equipment grant AKUL/13/09) and funding from the King Baudouin Foundation United States (KBFUS gran n° 20160139), made possible thanks to the generous contribution of Landon T. Clay. We acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with the support of the Dutch Heart Foundation, CVON2016-Early HFPEF, CVON 2017-ShePREDICTS and ERA-CVD funding (FWO G0H7716N). This project was also supported by a joined PhD funding program in the framework of the cooperation between Maastricht University and Liege University named "Towards a joint imaging valley".

Author Contributions

V.C. conceptualized the work, performed investigations and wrote the manuscript; Q.R., P.C., I.C., L.P., E.L.R. and K.D. performed investigations and reviewed/edited the manuscript; J.L., A.N., E.A.V.J., L.M. and J.S. reviewed/edited the manuscript; S.H. conceptualized the work, wrote the manuscript and supervised the work.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-018-29812-w>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018